|
|
Post by cm5 on Aug 2, 2016 18:23:25 GMT -5
|
|
|
|
Post by cm5 on Aug 2, 2016 11:58:21 GMT -5
|
|
|
|
Post by cm5 on Aug 2, 2016 10:34:36 GMT -5
|
|
|
|
Post by cm5 on Aug 2, 2016 10:26:05 GMT -5
Per trondisc post: "Just read the entire article assessment over at MassDevice.c0m (if I post the link here this thread will be moved over and transferred to the articles, blog, media, etc. page so just do a damn search to find it). This information caught my attention... ' With all of the data provided for the G5 CGM, Dexcom is likely to win a favorable vote in the panel, according to Leerink Partners analyst Danielle Antallfy.
In our view, the panel docs are largely benign and support our belief that the panel will vote favorably that the benefits of a nonadjunctive claim outweigh the risks,” Antalffy wrote in a letter to investors. “As a reminder, the importance of a dosing claim centers not only around increased convenience to the patient — potentially further accelerating patient adoption — and validation of the technology, which could drive a higher number of physicians to prescribe, but also the possibility of securing CMS coverage, which would provide access to the 20%+ of Type 1 patients currently covered by Medicare.”
The roster of authorities sitting on the panel will work in Dexcom’s favor as well, Antallfy said, as it includes 6 endocrinologists and diabetes authorities, who the analyst thinks would “likely be more postively biased towards CGM.' "Read more: h ttp://mnkd.proboards.com/thread/5883/dxcm-verge-approval-implications-mnkd#ixzz4GBlfZtX1
Danielle Antalffy, Wall Street Analyst at Leerink Swann
Main Sector:Healthcare
Ranked #140 out of 4,083 Analysts(#221 of 9,427 overall experts) (over one year) |
|
|
|
Post by cm5 on Aug 2, 2016 10:21:12 GMT -5
And, on what date, etc, would such reports be publicly available?
|
|
|
|
Post by cm5 on Aug 2, 2016 9:56:56 GMT -5
|
|
|
|
Post by cm5 on Aug 2, 2016 7:28:59 GMT -5
Yes, but----as per prior posts in this thread: Mannkind: A Growing Threat To The Status Quo
|
|
|
|
Post by cm5 on Jul 31, 2016 17:41:23 GMT -5
|
|
|
|
Post by cm5 on Jul 31, 2016 17:19:24 GMT -5
Better we should be considering Metformin for helping prevent cancer, etc etc etc Anti-tumor effects of metformin in animal models of hepatocellular carcinoma: a systematic review and meta-analysis.www.ncbi.nlm.nih.gov/pubmed/26030161 |
|
|
|
Post by cm5 on Jul 31, 2016 13:11:44 GMT -5
Rereading irrationalexubera's post and going through past posts by same, I don't think it's correct to label above post as FUD----rather it could be easily interpreted by other posters to be FUD---just not absolutely clear with this a post asking for more info about what can be talked about, and assuming a big problem that is not a big problem  |
|
|
|
Post by cm5 on Jul 31, 2016 12:13:07 GMT -5
|
|
|
|
Post by cm5 on Jul 31, 2016 11:47:59 GMT -5
|
|
|
|
Post by cm5 on Jul 18, 2016 20:11:57 GMT -5
|
|
|
|
Post by cm5 on Jul 17, 2016 16:04:52 GMT -5
To give some perspective--see below. And, insulin analogues circulate far longer, sometimes many many hours.
And, please recall that 100% of circulatory output from heart is pumped at least several times a minute through the heart. So, alveolar endothelial cells continue to be exposed to insulin for hours.
|
|
|
|
Post by cm5 on Jul 17, 2016 15:22:52 GMT -5
Seems that many are distracted by simple complexities (yes, oxymoron, meaning obvious/expected technical/timing difficulties)
of the new roll out of Afrezza for July 25, 2016.
Time to remind all again of what is possible with Afrezza---in particular, in reference to IDE's, Insulin Degrading Enzymes.
|
|
